Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Clinics and Research in Hepatology and Gastroenterology|February 14, 2012
HCC and NASH: how strong is the clinical demonstration?O Rosmorduc, L FartouxAlimentary Pharmacology & Therapeutics|September 1, 2017
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year periodR Pais, L Fartoux, C Goumard, et al.Gastroenterologie Clinique Et Biologique|July 16, 2010
Antiangiogenic therapies in portal hypertension: a breakthrough in hepatologyO RosmorducBritish Journal of Cancer|February 25, 2009
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyT André, J M Reyes-Vidal, L Fartoux, et al.Gastroenterologie Clinique Et Biologique|June 12, 2010
The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adultsR Poupon, L Arrive, O RosmorducGastroenterology|April 21, 2001
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasisO Rosmorduc, B Hermelin, R PouponJournal of Virology|February 27, 2001
Inhibition of hepatitis B virus replication by the interferon-inducible MxA proteinE Gordien, O Rosmorduc, C Peltekian, et al.Hepatology (Baltimore, Md.)|August 8, 1998
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapyO Chazouillères, D Wendum, L Serfaty, et al.Gastroenterologie Clinique Et Biologique|January 1, 1992
[Severe hepatic steatosis: a cause of sudden death in the alcoholic patient]O Rosmorduc, J P Richardet, A Lageron, et al.Hepatology (Baltimore, Md.)|May 29, 1999
Bile acids modulate the interferon signalling pathwayP Podevin, O Rosmorduc, F Conti, et al.Pageof 3